IFL

(redirected from Irinotecan, Fluorouracil, and Leucovorin)
Category filter:
AcronymDefinition
IFLInternational Fight League (mixed martial arts)
IFLIndoor Football League
IFLInstitute for Learning (various locations)
IFLIn for Later
IFLImplementation and Application of Functional Languages (Symposium)
IFLIsrael Football League
IFLIrinotecan, Fluorouracil, and Leucovorin (cancer treatment)
IFLInsight for Living
IFLImage File List
IFLInter Facility Link
IFLIntegrated Facility for Linux (IBM)
IFLInterest Free Loan
IFLIntense Football League
IFLInstitute of Foreign Languages (Phnom Penh, Cambodia)
IFLInterfacility Link (satellites)
IFLI'm Feeling Lucky (Google)
IFLIndependent Flair League
IFLInstitute for Leaders
IFLImage File List (sequencing)
IFLInternational Friendship League
IFLIronman Football League (est. 1996)
IFLImage Format Library (software)
IFLInternational Frequency List
IFLIntegrated Facilities for Linux
IFLIrish Football League
IFLInternet Football League
IFLleukocyte interferon
IFLI Found Love
IFLIntroduction to Foreign Language (various schools)
IFLInfra-Free Life
IFLIn Fake Life
IFLInstitute for Financial Literacy, Inc.
IFLIslamic Foundation of Lincoln (Nebraska)
IFLIntermediate Flight Level
IFLInterferon Leukocyte
IFLIntegrated Foundation Library
IFLInterim Fast Lane
IFLIdeas for Life
IFLInterfacility Unit
IFLIn-Flight Lock (safety device on a missile launcher)
IFLIsleboro Free Library (Isleboro, ME)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Novotny et al., "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," The New England Journal of Medicine, vol.
Fehrenbacher, W Novotny et al., "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," The New England Journal of Medicine, vol.
Two new additions to chemotherapy regimens for colorectal cancer--bevacizumab added to irinotecan, fluorouracil, and leucovorin; and oxaliplatin added to fluorouracil and leucovorin--improved overall or disease-free survival, according to two multicenter, randomized trials.
More than 900 patients with metastatic colorectal cancer were randomly assigned to receive standard combination chemotherapy with irinotecan, fluorouracil, and leucovorin (IFL) plus bevacizumab (Avastin), IFL plus placebo, or fluorouracil and leucovorin plus bevacizumab.
More than 900 patients who had metastatic colorectal cancer were randomly assigned to receive standard combination chemotherapy with irinotecan, fluorouracil, and leucovorin (IFL) plus bevacizumab (Avastin), IFL plus placebo, or fluorouracil and leucovorin plus bevacizumab.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer.